IFF

International Flavors & Fragrances Inc.

Next est. report 2026-11-03 · AMC

GLP-1 Long '24: Healthy FoodsPackaged Foods '26: Ingredients & FlavoringPackaged Foods '26: Non-Coffee Beverages

Loading…

Loading chart…

Overview

International Flavors & Fragrances Inc. (IFF) is a global leader in essential ingredients and solutions. The company focuses on its core Taste, Scent, and Healt

International Flavors & Fragrances Inc. (IFF) is a global leader in essential ingredients and solutions. The company focuses on its core Taste, Scent, and Health & Biosciences segments. IFF creates flavor compounds for food and beverages, fragrances for perfumes and consumer products, and specialized biological ingredients like enzymes and probiotics. It serves a diverse customer base of manufacturers in consumer goods, food, and beverage industries worldwide.

Search Keywords Brand Product

LMR Naturals
HOWARU Probiotics
SENSORA technology
FlavorFit technology
Fragrance Ingredients
Fine Fragrances
Consumer Fragrances
Food Biosciences
Taste Solutions
Health & Biosciences ingredients
flavor and fragrance industry
specialty ingredients
food and beverage innovation
health and wellness trends
sustainability in ingredients
R&D investment
portfolio transformation
divestiture strategy
GLP-1 impact on food
clean label products
high protein foods

Search Keywords Event Phrases

IFF Food Ingredients divestiture
Q2 2026 earnings IFF

What They Do (Plain English & Analogies): IFF (International Flavors & Fragrances Inc.) is like a behind-the-scenes wizard for many of the products you use every day. They create the essential 'secret ingredients' that make your food taste delicious, your perfumes smell captivating, and your personal care products perform better. Imagine them as master chefs developing unique flavors for snacks and drinks, expert perfumers crafting scents for everything from luxury perfumes to laundry detergents, and scientists creating specialized ingredients like probiotics and enzymes that boost health, improve food quality, and even enhance industrial processes. After recent strategic changes, IFF is now sharply focused on these core areas: Taste, Scent, and Health & Biosciences.
Very Brief History: International Flavors & Fragrances Inc. (IFF) was founded in 1958 through the merger of two established companies, Polak & Schwarz and van Ameringen-Haebler. The company expanded significantly over the decades, notably acquiring Frutarom in 2018 and merging with DuPont's Nutrition & Biosciences (N&B) business in 2021. In 2026, IFF embarked on a major portfolio transformation, including the announced divestiture of its Food Ingredients business, to streamline operations and concentrate on its higher-growth, higher-margin Taste, Scent, and Health & Biosciences segments.
"Street Stereotype": IFF is currently perceived by investors and analysts as a company in the midst of a significant transformation and turnaround. Following a period of complexity and underperformance after large acquisitions, the 'street stereotype' is that IFF is now actively 'rightsizing' and 'simplifying' its business through strategic divestitures. The market views it as an 'actionable recovery' story, aiming to unlock value by focusing on its high-value Taste, Scent, and Health & Biosciences businesses, with the potential to close the valuation gap with peers like Givaudan and Symrise if the restructuring and execution are successful.
Subsidiaries On Linked In*: {"subsidiaries":[]}
Customer Sectors & Example Clients: IFF's customers operate in diverse sectors, including perfumery, cosmetics, hair and personal care, soaps and detergents, cleaning products, dairy, meat and processed foods, beverages, snacks and savory items, sweet and baked goods, dietary supplements, infant and elderly nutrition, functional foods, and producers of pharmaceutical excipients and oral care products. Based on its industry position and the transcript, example clients likely include major global consumer goods companies such as Procter & Gamble (mentioned in the context of probiotics), Unilever, Nestlé, PepsiCo, and Coca-Cola.
New Customers / Segments They'Re Targeting: IFF is actively targeting customers who are innovating around long-term megatrends in health, well-being, food, and sustainability. This includes reaching new customer segments focused on developing 'higher protein consumer products' and 'clean label' offerings. The company is proactively engaging with clients to create products that address the opportunities presented by GLP-1 drugs, focusing on healthier, great-tasting, and high-protein options. Additionally, IFF is strengthening its commercial capabilities and R&D pipeline in Health & Biosciences, particularly for probiotics, and investing in new molecules and delivery systems within the Scent segment.
Sales Geographies And Expansion Plans: IFF currently sells its products across major global regions, including Europe, Africa, the Middle East, Greater Asia, North America, and Latin America. In the second quarter of 2026, the company reported sales growth across 'all regions' for its Taste segment and 'all businesses' for Health & Biosciences. While no specific new geographic expansion plans were explicitly disclosed in the recent earnings call, management indicated a focus on scaling organically and through bolt-on acquisitions within its three core businesses globally.
How Key Themes May Help/Hurt: The 'GLP-1 Long '24: Healthy Foods' theme is expected to significantly benefit IFF. The company views the rise of GLP-1 drugs and the broader consumer shift towards healthier, higher-protein, and clean-label food products as a major opportunity. IFF is proactively collaborating with customers to develop innovative flavors and food-related bioscience solutions that enable the creation of healthier, great-tasting, and high-protein products, directly aligning with these evolving consumer preferences. The Health & Biosciences segment, with its focus on probiotics and enzymes, is particularly well-positioned to capitalize on the increased demand for functional and health-enhancing ingredients.

3 Main Long-Term Bull Details

Focused Portfolio Transformation: The strategic divestiture of the Food Ingredients business and other non-core assets allows IFF to concentrate entirely on its higher-growth, higher-margin Taste, Scent, and Health & Biosciences segments, which are better aligned with long-term consumer megatrends in health, well-being, and sustainability.
Strengthened Financial Position: IFF is utilizing proceeds from divestitures to reduce debt by over $1 billion and execute a $2.5 billion share repurchase program, which is expected to significantly strengthen its balance sheet and improve its net debt to EBITDA leverage, thereby enhancing long-term shareholder value.
Enhanced Innovation and R&D Investment: The company has substantially increased its R&D capabilities and spend (now around 9% of sales for its core businesses) to drive leading innovation, develop cutting-edge molecules and delivery systems, and capture market share in its key segments. This commitment to R&D is a crucial driver for future organic growth and competitive differentiation.

3 Main Long-Term Bear Details

Temporary Stranded Costs: The divestiture of the Food Ingredients business has resulted in approximately $100 million in stranded corporate and functional costs, which are temporarily pressuring the margins of the remaining businesses. While a remediation plan is underway, the full elimination of these costs is expected to take up to two years.
Macroeconomic and Geopolitical Volatility: Ongoing market uncertainties, including inflationary pressures and geopolitical conflicts (such as the Middle East conflict impacting Fine Fragrance), could continue to affect consumer demand, input costs, and overall business performance, creating headwinds for sales growth and profitability.
Execution Risks of Transformation: Despite the clear strategic direction, the company faces execution risks related to the successful and timely separation of the divested businesses, managing potential working capital headwinds during the transition, and effectively integrating the remaining portfolio to fully realize the anticipated margin expansion and growth targets.

Competitors And Differentiation: IFF's primary competitors in the flavors and fragrances industry include Givaudan, Symrise, and Robertet. IFF differentiates itself through its commitment to 'leading innovation,' backed by a significantly strengthened R&D pipeline, with R&D spend for its remaining businesses increasing from approximately 7% to 9% of sales. The company emphasizes its strong commercial capabilities and its ability to deliver 'high-value solutions' that address evolving customer and market needs. IFF leverages its shared naturals and biotech capabilities across its Taste, Scent, and Health & Biosciences segments to create unique, technology-enabled flavor designs and pioneering fragrance solutions.
Recent Performance & What The Market'S Focused On: IFF delivered strong financial results in the second quarter of 2026 on a continuing operations basis, with revenue increasing approximately 6% to just under $2 billion and adjusted operating EBITDA growing 6% to $408 million. This performance was broad-based, driven by volume growth across all segments, including high single-digit growth in Scent and mid-single-digit increases in Taste and Health & Biosciences. The company also generated robust free cash flow of $378 million in the first half of 2026, a significant year-over-year improvement. The market is primarily focused on the successful completion of the Food Ingredients divestiture, the effective reduction of stranded costs, and the sustained profitable growth of the remaining Taste, Scent, and Health & Biosciences businesses. Investors are also closely tracking IFF's progress in strengthening its balance sheet through debt reduction and share repurchases, and its ability to navigate macroeconomic uncertainties while delivering on its strategic goals.

Revenue Segments And Estimated Mix: Taste — Mix: ~35.2%; Source: Q2 2026 earnings transcript; Trend: Sales grew 4% in Q2 2026, led by double-digit performance in Asia. Growth driven by new wins and existing business volume.
Scent — Mix: ~34.0%; Source: Q2 2026 earnings transcript; Trend: Sales grew 8% in Q2 2026, driven by double-digit growth in Fragrance Ingredients and high single-digit in Consumer Fragrance. Fine Fragrance grew low single digits despite Middle East conflict.
Health & Biosciences — Mix: ~30.7%; Source: Q2 2026 earnings transcript; Trend: Sales grew 5% in Q2 2026, with growth in all businesses, notably Grain Processing, Food Biosciences, and Animal Nutrition.
Product Brands: LMR Naturals
HOWARU®
Thrive4U
CARE4U®
BioVia®
MicroGARD®
Natamax®
Nisaplin®
NovaGARD®
GUARDIAN™
SUPRO®
RESPONSE®
ALPHA®
TRUPRO®
SUPRO® MAX
SUPRO® TEX
Cashmeran™
ISO E Super
Amber Xtreme™
SENSORA™
FlavorFit™
GENENCARE® Actives
AURIST™ Functionals

Bull / Bear Details

IFF's strategic transformation, driven by the divestiture of its Food Ingredients business, positions it as a more focused, higher-growth, and higher-margin ent

Thesis

IFF's strategic transformation, driven by the divestiture of its Food Ingredients business, positions it as a more focused, higher-growth, and higher-margin entity in Taste, Scent, and Health & Biosciences. Strengthened financials through debt reduction and share repurchases, coupled with a proactive innovation strategy addressing trends like GLP-1, reinforce a bullish outlook. However, temporary stranded costs and ongoing macroeconomic volatility present near-term challenges. (August 31, 2026)

Bull case

The divestiture of the Food Ingredients business and other non-strategic assets streamlines IFF's portfolio, focusing on higher-growth, higher-margin Taste, Scent, and Health & Biosciences segments. This strategic simplification aligns with long-term consumer megatrends and is expected to accelerate innovation, improve execution, and enhance free cash flow conversion.
IFF is significantly strengthening its financial position by reducing debt by over $1 billion and initiating a $2.5 billion share repurchase program, with $500 million planned for H2 2026. This capital allocation strategy aims for a net debt to EBITDA ratio of 2.0x-2.5x by end of 2027, signaling confidence in future value creation and improving shareholder returns.
IFF is proactively addressing evolving market needs, such as the GLP-1 and clean label trends, by increasing R&D spend (now ~9% of sales for Remainco) and developing high-protein, great-tasting, and healthier product solutions. This innovation-driven approach is fueling strong volume growth across its core segments and enhancing its competitive moat.

Bear case

The divestiture of Food Ingredients creates approximately $100 million in stranded corporate and functional costs that will temporarily pressure the margins of the remaining businesses. While IFF has a remediation plan, eliminating two-thirds of these costs within 12 months and the remainder in the second year means a prolonged impact on profitability.
Ongoing macroeconomic pressures, including inflationary costs (especially energy and logistics) and geopolitical volatility, particularly in the Middle East, introduce uncertainty. While consumer demand has been resilient, these factors could lead to moderated growth in the second half of 2026 and potential shifts in consumer spending towards more affordable options.
IFF expects a couple of hundred million dollars in working capital headwinds in the second half of 2026 due to the separation and stand-up of the Food Ingredients business. Additionally, there is a recognized lag in pricing recovery, particularly in the Scent segment, which may temporarily compress margins as input costs modestly increase.

Bull / Bear Case

Bear Case: The bear case for IFF centers on several near-term challenges and execution risks. The divestiture of Food Ingredients creates approximately $100 million in stranded corporate and functional costs, which will temporarily pressure the margins of the remaining businesses, with full elimination taking up to two years. Ongoing macroeconomic pressures, including inflationary costs (especially energy and logistics) and geopolitical volatility in the Middle East, introduce uncertainty and could moderate growth in the second half of 2026. Furthermore, IFF anticipates a "couple of hundred million dollars" in working capital headwinds in H2 2026 related to the divestiture, coupled with a recognized lag in pricing recovery, particularly in the Scent segment, which may temporarily compress margins. Moderating growth expectations for H2 and continued market challenges in the U.S. health business add to the headwinds.
Bull Case: International Flavors & Fragrances Inc. presents a compelling bull case driven by its strategic portfolio transformation. The divestiture of the Food Ingredients business and other non-strategic assets streamlines IFF's focus on higher-growth, higher-margin Taste, Scent, and Health & Biosciences segments, aligning with long-term consumer megatrends. This simplification is expected to accelerate innovation, improve execution, and enhance free cash flow conversion. IFF is strengthening its financial position through over $1 billion in debt reduction and a $2.5 billion share repurchase program, targeting a net debt to EBITDA of 2.0x-2.5x by end of 2027. Increased R&D spend (now ~9% of sales) and proactive engagement with trends like GLP-1 are fueling strong volume growth and competitive differentiation. The solid Q2 2026 results and raised full-year guidance underscore confidence in this trajectory.
More Compelling & Why: Bull. The market's strong positive reaction, with IFF significantly outperforming the SPY since the earnings call, implies a favorable valuation of the ongoing portfolio transformation. The strongest argument is the clear path to a higher-growth, higher-margin business, supported by debt reduction, substantial share repurchases, and increased R&D. This strategic shift is expected to enhance free cash flow generation, which, if realized at the projected mid-to-high teens as a percentage of sales for Remainco, would justify a premium valuation. My view would flip if the execution of stranded cost elimination or the divestiture is significantly delayed, or if macroeconomic headwinds materially impact volume growth in the core segments.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Net Debt to Credit-Adjusted EBITDA Leverage	Strengthening the balance sheet is a key strategic priority. Reaching the target leverage range of 2.0x to 2.5x by the end of 2027 significantly improves financial flexibility and reduces risk, enhancing investor confidence.	Observe reported net debt to credit-adjusted EBITDA leverage at the end of Q3 and Q4 2026. Monitor management commentary on the trajectory towards the 2.0x-2.5x target by end of 2027, especially considering the temporary increase from initial share repurchases.	Bullish: Leverage ratio trending downwards towards the 2.0x-2.5x target, even with initial share repurchases, and management reiterates confidence in achieving the target by end of 2027. Bearish: Leverage ratio increases significantly or remains elevated, and management expresses concerns about achieving the target.	Company earnings calls and press releases, SEC filings (10-Q, 10-K).	Financial news and analyst reports tracking IFF's debt metrics.	S&P Global Market Intelligence: IFF credit ratings, debt covenants, and leverage ratios.
Free Cash Flow Generation (excluding divestiture headwinds)	Robust free cash flow is essential for debt reduction, share repurchases, and reinvestment in growth businesses. It reflects operational efficiency and disciplined working capital management, which are key management focus areas.	Monitor reported free cash flow for Q3 and Q4 2026. Observe management commentary on the impact of the 'couple of hundred million dollars' in working capital headwinds related to the Food Ingredients stand. Confirm free cash flow for full year 2026 is higher than 2025, inclusive of headwinds.	Bullish: Free cash flow for 2026 significantly exceeds 2025 levels, despite headwinds, and management provides strong outlook for Remainco FCF conversion (mid-to-high teens as % of sales). Bearish: Free cash flow for 2026 is flat or lower than 2025, or working capital headwinds are larger/more prolonged than expected.	Company earnings calls and press releases, SEC filings (10-Q, 10-K).	Industry reports on working capital management best practices in the chemicals/ingredients sector.	FactSet/Refinitiv: IFF cash flow statements, working capital trends, and analyst estimates for FCF.
Stranded Cost Elimination Progress	The $100 million in stranded costs temporarily pressure business unit margins. Successful and timely elimination is crucial for achieving strong EBITDA margin expansion and enhancing the profitability of the remaining IFF portfolio.	Look for management updates on the remediation plan. Confirm the elimination of approximately two-thirds of the $100 million in stranded costs within the first 12 months following transaction close, and the remainder within the second full year.	Bullish: Management reports achieving or exceeding the target of eliminating 2/3 of stranded costs within the first 12 months post-close, with clear plans for the remainder. Bearish: Delays in cost elimination, or an increase in the estimated stranded costs.	Company earnings calls and transcripts, investor presentations, SEC filings (10-Q, 10-K).	Industry news on corporate restructuring or efficiency initiatives in the specialty chemicals sector.	S&P Global Market Intelligence: IFF margin analysis, cost structure changes.
Continuing Operations Sales Growth (Volume-Driven)	Volume growth is the primary driver of IFF's top-line performance and indicates strong customer demand and successful innovation in its core, higher-margin businesses. This underpins confidence in full-year targets.	Monitor Q3 and Q4 2026 earnings reports for sales growth in Taste, Scent, and Health & Biosciences segments. Observe overall continuing operations sales growth within the updated full-year 2026 guidance range of 2% to 4% ($7.4 billion to $7.6 billion).	Bullish: Continuing operations sales growth consistently at or above the mid-point of the 2-4% guidance range, primarily driven by volume. Bearish: Sales growth falling below the low end of the guidance range, or growth primarily driven by pricing rather than volume.	Company earnings calls and press releases (Q3 2026 earnings estimated November 3, 2026), SEC filings.	Google Trends: Search volume for 'IFF flavors,' 'IFF fragrances,' 'IFF probiotics' (as a proxy for customer interest). Industry reports on specialty ingredients market growth.	NielsenIQ/IRI: Market share and sales trends for consumer products using IFF ingredients (indirect). Facteus/Consumer Edge: Consumer spending trends in relevant end markets (e.g., packaged foods, personal care).
Food Ingredients Divestiture Progress & H2 2026 Share Repurchase	This transaction is a defining step in IFF's portfolio transformation, focusing on higher-growth, higher-margin businesses. Successful execution of the H2 2026 share repurchases demonstrates management's confidence in long-term value creation and returns capital to shareholders.	Monitor updates on the transaction's progress towards closing by the end of Q2 2027. Confirm the execution of approximately $500 million in share repurchases during the second half of 2026.	Bullish: Transaction remains on track for Q2 2027 close, and the $500 million share repurchase is completed as planned in H2 2026. Bearish: Delays in the divestiture timeline or slower-than-expected execution of the H2 2026 share repurchase program.	Company press releases, SEC filings (8-K, 10-Q), IFF Investor Relations website (ir.iff.com).	Financial news aggregators for announcements related to IFF's divestiture and share repurchases.	Bloomberg Terminal: IFF share repurchase activity, M&A transaction status.

Key Reported Metrics, Reratings Triggers & Results3 rows

The Scent segment delivered the strongest growth in the last reported quarter and is a key part of IFF's focused, higher-margin portfolio post-divestiture. Sust

Upcoming print · 2026-11-03

Key reported metrics
Metric	Last period	Why it matters
Scent Segment Sales Growth	8%	The Scent segment delivered the strongest growth in the last reported quarter and is a key part of IFF's focused, higher-margin portfolio post-divestiture. Sustained strong performance here, especially with R&D investments and market share gains, is vital for overall revenue and profitability.
Adjusted Operating EBITDA Growth (Continuing Operations)	6%	EBITDA growth for continuing operations indicates the profitability and operational efficiency of IFF's core businesses post-divestiture. It's a key indicator of margin expansion potential, especially as the company works to eliminate stranded costs and drive productivity.
Continuing Operations Sales Growth	6%	This metric is crucial as IFF is undergoing a significant portfolio transformation. It reflects the performance of the newly focused, higher-growth, higher-margin core businesses (Taste, Scent, Health & Biosciences) and validates the strategic shift. Investors will be watching for sustained volume-driven growth in these segments.

Key Questions

Will IFF successfully execute the planned reduction of two-thirds of the $100 million in stranded costs within the first 12 months post-Food Ingredients divesti

Will IFF successfully execute the planned reduction of two-thirds of the $100 million in stranded costs within the first 12 months post-Food Ingredients divestiture, and how will this impact business unit margins in the next quarter?

Question 2: Can IFF sustain volume-driven sales growth in its continuing operations (Taste, Scent, Health & Biosciences) in the second half of 2026, particularly given expected moderation from Q2 and ongoing market volatility?
Question 3: Will IFF effectively manage the anticipated 'couple of hundred million dollars' in working capital headwinds related to the Food Ingredients divestiture in the second half of 2026, while also executing its planned $500 million share repurchases and maintaining its deleveraging trajectory?

Earnings Transcript SummaryTable

2026-08-04 · 2026Q2 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Portfolio Transformation and Simplification: Management is relentlessly focused on transforming IFF through the divestiture of the Food Ingredients business, aiming for a sharper focus on higher-growth, higher-margin Taste, Scent, and Health & Biosciences businesses. This includes addressing stranded costs from the divestiture to enhance profitability. 2. Driving Productivity and Cash Flow Improvements: A key focus is on delivering volume growth, disciplined margin execution, and robust free cash flow generation. This involves improving net working capital, effective inventory management, and disciplined accounts receivable and payable controls. 3. Leading Innovation and Customer Focus: Management emphasizes serving customers through leading innovation, strengthening R&D capabilities, and enhancing commercial pipelines to be more competitive and address evolving customer and market needs.	Call Takeaway & ToneThe overall takeaway of the call is that IFF delivered strong second-quarter results, driven by volume growth and productivity improvements, and is making significant progress on its portfolio transformation with the divestiture of Food Ingredients. The tone was positive and confident, with management emphasizing their ability to execute strategic initiatives, strengthen the balance sheet, and focus on higher-growth, higher-margin businesses. While acknowledging ongoing macroeconomic uncertainty and volatility, particularly in the Middle East, management expressed confidence in achieving full-year targets and driving long-term value creation through innovation, productivity, and disciplined capital allocation.	Prior Quarter'S Y/Y Growth By SegmentFor the first quarter of 2026, Taste segment sales increased 2% year-over-year. Health & Biosciences achieved 5% sales growth year-over-year. The Scent segment delivered 1% growth year-over-year. The Food Ingredients segment posted 3% sales growth year-over-year.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Future Divestitures/Portfolio Strategy: Analysts questioned if the Food Ingredients divestiture was the last, or if more portfolio trimming was expected. Management responded that they are exactly where they want to be with their portfolio, with no significant divestitures left, and the focus is now on scaling organically and through bolt-ons in the three core businesses. 2. Guidance for H2 and Underlying Volume Trends: Analysts inquired about the raised low end of the sales growth guidance and whether it implied improved second-half performance, or if it was a flow-through from the strong first half, particularly concerning underlying volumes amidst inflationary pressures. Management clarified that the increase in the low end of the range was essentially the flow-through of the strong first-half performance, and while core business growth remains solid, they expect second-half growth to moderate to low single-digits due to market uncertainty. They noted consumer demand has been resilient so far, with no significant changes heard from customers, but acknowledged risks. 3. Stranded Costs and Margin Expansion: Analysts pressed on the plans to offset stranded overheads, specifically why the timeline for elimination was extended to two years instead of one, and the expected trajectory of EBITDA margins for the remaining business. Management explained that the two-year timeline (2/3 in year 1, remainder by year 2) is the best approach to deal with the $100 million in stranded costs with minimum disruption to driving profitable growth in Scent, Taste, and Health & Biosciences, and they are confident this will support strong EBITDA margin expansion over the next few years.	Revenue SegmentsIn the second quarter of 2026, IFF's continuing operations generated revenue of just under $2 billion, up approximately 6% year-over-year. Segment-wise, Taste sales grew 4%, Health & Biosciences grew 5%, and Scent delivered strong 8% growth. Within Scent, Fragrance Ingredients saw double-digit growth, Consumer Fragrance increased high single-digits, and Fine Fragrance grew low single-digits. The divested Food Ingredients business, discussed on a combined basis for reference, grew 3%.

Transcript TidbitsTable

2026-08-04

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)
About Expanding Eligible MarketIFF's portfolio will have a sharper focus on higher growth, higher-margin Taste, Scent, and Health & Biosciences businesses following the divestiture of Food Ingredients. The streamlined portfolio is expected to align with long-term megatrends in health, well-being, food, and sustainability. The company plans to scale these three businesses organically and through bolt-on acquisitions. Taste, Scent, and Health & Biosciences are positioned for strong revenue and EBITDA growth, driven by shared naturals and biotech capabilities.	About CompetitionIFF views China as a critically important market and will not underestimate Chinese competitors, committing to rigorous competition through leading innovation. The company has significantly increased its R&D capabilities and spend over the last 2.5 years, from about 7% to 9% of sales for the Remainco businesses, and will continue to increase R&D spend as sales grow, considering further increases if it creates additional value. The Scent team is working to rebuild R&D capability and go-to-market approach to drive market share gains, and is shifting Fragrance Ingredients towards higher-value natural products to build a strong competitive position.	About The Broader IndustryMarket conditions remain uncertain due to events in the Middle East, and the company acknowledges ongoing volatility. Consumer demand has been resilient despite uncertainties and inflationary pressures, with no significant changes observed from customers yet. Input costs, particularly energy and logistics, are expected to increase modestly in the second half of the year. There is a recognized lag in pricing recovery in some instances, specifically in the Scent segment, to offset these inflationary pressures. The company is proactively addressing the GLP-1 and ultra-processed foods trend as an opportunity, noting strong growth in flavors and food-related Biosciences by enabling high-protein, great-taste, healthier products and leaning into clean label opportunities.	Where Things Are HeadedIFF is undergoing a transformation with the divestiture of Food Ingredients, aiming for a sharper focus on higher-growth, higher-margin Taste, Scent, and Health & Biosciences businesses. The company expects to eliminate approximately two-thirds of the $100 million in stranded costs within the first 12 months post-transaction close, and the remainder within the second full year, which is anticipated to support strong EBITDA margin expansion. Proceeds from the Food Ingredients divestiture will be used to reduce debt by over $1 billion, targeting a net debt to EBITDA ratio between 2.0x and 2.5x by the end of 2027, and for a $2.5 billion share repurchase program, with $500 million expected in the second half of 2026. For full year 2026, sales are projected to be between $7.4 billion and $7.6 billion (2% to 4% growth), and EBITDA between $1.53 billion and $1.6 billion (4% to 8% growth). The company plans to continue increasing R&D spend as sales grow and will maintain CapEx in the 5% to 6% of sales range, potentially at the upper end for the next one to two years due to high-return initiatives. The remaining businesses are expected to drive strong free cash flow generation, with mid- to high teens cash flow as a percentage of sales.	Updates On ThemeHealthy	Broader Themes EmergingLong-term megatrends in health, well-being, food and sustainability.	Bullish-Leaning Quotes (Short)IFF's strong second quarter results reflect our relentless focus on our customers while driving productivity and cash flow improvements. IFF delivered volume growth across the board, disciplined margin execution and robust free cash flow generation, strengthening our financial position. We are transforming IFF with the divestiture of Food Ingredients and a solid first half of 2026 gives us confidence in our ability to achieve our targets for the full year. IFF will have a sharper focus around our higher growth, higher-margin Taste, Scent and Health & Biosciences businesses. We are confident in our ability to execute this plan and over time, eliminate these costs while enhancing the profitability and earnings power of the remaining IFF portfolio. This reflects our confidence in IFF's long-term value creation opportunities and the compelling return profile of repurchases at current valuation levels. Our continuing operations portfolio is durable, diverse and grounded in essential products and solutions, giving us a strong foundation in an uncertain and volatile environment. The growth for the core business remains solid. Consumer demand has been resilient so far this year. The flavors and food-related Biosciences have been growing very strongly in total and in significant part because instead of looking at these as negatives, as we've looked at them as opportunities. I think we've got a very strong R&D capability. The best is yet to come.	Bearish-Leaning Quotes (Short)Market conditions remain uncertain due to the events in the Middle East. With the Food Ingredients divestiture, there are stranded costs that represent about $100 million of corporate and functional expenses previously allocated to the Food Ingredients business that are expected to remain with IFF. These costs are now spread amongst the remaining businesses of Taste, Scent and Health & Biosciences and are currently temporarily pressuring the business unit margins. While we're not immune to macroeconomic pressures, including ongoing volatility in the Middle East, we believe we can successfully navigate the environment. We are conscious that the world remains volatile, which is reflected in our full year guidance range. We do expect it [second half growth] to moderate from the 6% we reported in Q2. While the Middle Eastern crisis continues, we are factoring in a softer Q3 [for Fine Fragrance]. There could be some working capital headwinds related to the Food Ingredients divestment in the second half. Specifically, just to size that, that could be a couple of hundred million dollars. We see continued growth in our health business outside the U.S., but continued market challenges in the U.S. Embedded in the guidance is a little bit of a press on price to input cost or raw material cost. Fragrance Ingredients number, it was very strong in Q2. We do believe that as we go forward, that will normalize on a go-forward basis.

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	Price Reaction
2026-08-04	IFF's Q2 2026 earnings showed strong 6% organic revenue growth in continuing operations, driven by volume across segments. Management's confident tone regarding portfolio transformation, debt reduction, and a $2.5 billion share repurchase program was well-received. Despite missing analyst estimates for overall revenue and EPS, the stock significantly outperformed SPY (6.18% vs 0.25% T+2), indicating market approval of the underlying business performance and strategic direction.	Earnings Transcript	Positive		+6.18% (vs SPY: +5.93%)